Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELUNASDAQ:EPIXNASDAQ:GLSINASDAQ:GTHX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$1.76+0.6%$1.85$1.00▼$5.22$42.15M0.77335,748 shs9,075 shsEPIXESSA Pharma$1.70+1.8%$1.70$1.40▼$7.88$74.13M1.58339,167 shs40,374 shsGLSIGreenwich LifeSciences$9.20$9.63$8.06▼$18.75$122.99M1.6946,655 shs27,956 shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/A13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity0.00%-15.87%-14.22%+17.45%-45.40%EPIXESSA Pharma0.00%-2.34%-2.34%+4.37%-68.90%GLSIGreenwich LifeSciences0.00%-4.76%-5.54%-24.65%-37.67%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+157.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELUCelularity0.5197 of 5 stars0.02.00.00.01.91.70.6EPIXESSA Pharma2.0061 of 5 stars2.03.00.00.02.72.51.3GLSIGreenwich LifeSciences2.2609 of 5 stars3.51.00.00.02.73.30.0GTHXG1 Therapeutics0.3985 of 5 stars1.00.00.03.80.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 0.00N/AN/AN/AEPIXESSA Pharma 2.00Hold$2.0017.65% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00323.91% UpsideGTHXG1 Therapeutics 2.00Hold$4.00-44.06% DownsideCurrent Analyst Ratings BreakdownLatest GLSI, CELU, GTHX, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$54.22M0.78$7.33 per share0.24$2.11 per share0.83EPIXESSA PharmaN/AN/AN/AN/A$2.68 per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/AGTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$196.29M-$2.65N/A∞N/A-72.72%-119.53%-25.40%7/28/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-24.61%-23.87%8/4/2025 (Estimated)GLSIGreenwich LifeSciences-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/ALatest GLSI, CELU, GTHX, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularityN/A0.190.14EPIXESSA PharmaN/A33.1233.12GLSIGreenwich LifeSciencesN/A6.916.91GTHXG1 Therapeutics1.342.482.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%EPIXESSA Pharma75.12%GLSIGreenwich LifeSciences4.16%GTHXG1 Therapeutics24.21%Insider OwnershipCompanyInsider OwnershipCELUCelularity22.10%EPIXESSA Pharma15.50%GLSIGreenwich LifeSciences51.67%GTHXG1 Therapeutics6.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22023.95 million18.55 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableGLSIGreenwich LifeSciences313.37 million6.35 millionNot OptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableGLSI, CELU, GTHX, and EPIX HeadlinesRecent News About These CompaniesDrug developer seeks $100M for new cancer treatmentDecember 20, 2024 | bizjournals.comPharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender OfferSeptember 18, 2024 | globenewswire.comTrilaciclib by G1 Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of ApprovalSeptember 9, 2024 | pharmaceutical-technology.comWhy G1 Therapeutics Inc (GTHX) Stock is Currently 0.40% Above from Its 20-Day SMA?September 6, 2024 | bovnews.comG1 Therapeutics Inc.August 30, 2024 | barrons.comWhat’s Causing G1 Therapeutics Inc (GTHX) Stock’s 220.72% Jump Over the Last Six Months?August 24, 2024 | bovnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of ShareholdersAugust 20, 2024 | stockhouse.comGTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.August 9, 2024 | globenewswire.comHold Rating Affirmed Amid G1 Therapeutics’ Acquisition by PharmacosmosAugust 9, 2024 | markets.businessinsider.comIn $400M deal for Triangle firm, familiar name is largest shareholderAugust 9, 2024 | bizjournals.comNeedham Downgrades G1 Therapeutics (GTHX)August 9, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of ShareholdersAugust 9, 2024 | globenewswire.comG1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2024 | zacks.comG1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational HighlightsAugust 8, 2024 | globenewswire.comG1 Therapeutics Shares Hit 52-Week High on Deal to Be AcquiredAugust 7, 2024 | marketwatch.comGTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to ShareholdersAugust 7, 2024 | stockhouse.comRTP company taken private in $405 million dealAugust 7, 2024 | bizjournals.comG1 Therapeutics To Be Acquired By Pharmacosmos For $7.15/shr In CashAugust 7, 2024 | markets.businessinsider.comG1 Therapeutics Q2 2024 Earnings PreviewAugust 7, 2024 | msn.comG1 Therapeutics Stock Skyrockets 65% on $405 Million Merger Deal—What’s Next?August 7, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLSI, CELU, GTHX, and EPIX Company DescriptionsCelularity NASDAQ:CELU$1.76 +0.01 (+0.57%) Closing price 04:00 PM EasternExtended Trading$1.75 -0.01 (-0.57%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.ESSA Pharma NASDAQ:EPIX$1.70 +0.03 (+1.80%) Closing price 04:00 PM EasternExtended Trading$1.67 -0.03 (-1.71%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Greenwich LifeSciences NASDAQ:GLSI$9.20 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$9.19 -0.01 (-0.11%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
